DGAP-News: Is BioLife Sciences (OTCPK: BLFE) An OTC Company Primed For Growth?
Retrieved on:
Tuesday, August 16, 2022
Survival, Type 37, SEC, Textile, Plant, Enzyme, VOIP, Marketing, Filter (signal processing), Company, Acquisition, COO, BLFE, Gaps, OTCQB, Growth, Human, Severe acute respiratory syndrome coronavirus 2, Advertising, Animal, Innovation, OTC Markets Group, Immune system, Health, Security (finance), Copper, Fertilizer, Dietary supplement, Baxter International, Copper
Is BioLife Sciences (OTCPK: BLFE) An OTC Company Primed For Growth?
Key Points:
- Is BioLife Sciences (OTCPK: BLFE) An OTC Company Primed For Growth?
- BioLife Sciences Inc. (BioLife), a commercialization accelerator, licensor and developer of technologies, has reportedly provided investors with a significant company update throughout the course of a two-year transformation.
- Lets take a look at some of what the company has been up to over the last two years.
- In February of 2022, BioLife completed the acquisition of Health Box LLC an Arizona-based orthomolecular medicine and natural health products company.